NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$42.26
-2.42 (-5.42 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$41.53
Now: $42.26
$45.20
50-Day Range
$39.59
MA: $44.27
$49.27
52-Week Range
$26.80
Now: $42.26
$58.35
Volume212,179 shs
Average Volume236,600 shs
Market Capitalization$2.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Xencor logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900
Employees202
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.70 million
Cash Flow$0.54 per share
Book Value$10.46 per share

Profitability

Net Income$26.88 million
Net Margins-113.40%

Miscellaneous

Market Cap$2.45 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Xencor (NASDAQ:XNCR) Shares Gap Up to $40.81
March 31, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

939th out of 2,024 stocks

Pharmaceutical Preparations Industry

442nd out of 772 stocks

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$42.26
-2.42 (-5.42 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 2 sell ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

What stocks does MarketBeat like better than Xencor?

Wall Street analysts have given Xencor a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Xencor wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Tuesday, February, 23rd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.30. The biopharmaceutical company earned $41.85 million during the quarter, compared to analysts' expectations of $21.24 million. Xencor had a negative trailing twelve-month return on equity of 13.56% and a negative net margin of 113.40%.
View Xencor's earnings history
.

How has Xencor's stock price been impacted by Coronavirus?

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XNCR shares have increased by 50.3% and is now trading at $42.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XNCR?

9 analysts have issued twelve-month price targets for Xencor's shares. Their forecasts range from $21.00 to $59.00. On average, they anticipate Xencor's share price to reach $47.11 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 51, Pay $886.43k)
  • Mr. John J. Kuch, Sr. VP & CFO (Age 62, Pay $545.51k)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 57, Pay $599.29k)
  • Ms. Celia E. Eckert J.D., VP, Gen. Counsel & Corp. Sec. (Age 49, Pay $431.07k)
  • Dr. Allen S. Yang M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 53, Pay $199.38k)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Julie Casciani, Exec. Director of HR

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%), Crossmark Global Holdings Inc. (0.02%), EFG Asset Management Americas Corp. (0.02%) and Pacer Advisors Inc. (0.00%). Company insiders that own Xencor stock include Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor
.

Which major investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Pacer Advisors Inc.. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor
or view top insider-selling stocks.

Which major investors are buying Xencor stock?

XNCR stock was purchased by a variety of institutional investors in the last quarter, including EFG Asset Management Americas Corp., and Crossmark Global Holdings Inc..
View insider buying and selling activity for Xencor
or or view top insider-buying stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $42.26.

How much money does Xencor make?

Xencor has a market capitalization of $2.45 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 202 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

Where are Xencor's headquarters?

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.